Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
Brief
On "15/11/2024", the "European Medicines Agency (EMA)" issued an update regarding "Updated advice to minimise risks of interaction between weight loss medicine Mysimba and opioids". The EMA recommends updating the advice on minimising the risks of interaction between Mysimba, a weight loss medicine, and opioid-containing medicines. This is due to concerns that Mysimba may not work effectively in patients taking opioids and may increase the risk of rare but serious reactions such as seizures and serotonin syndrome.
Highlights content goes here...
Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
